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Abstract
Background: Amyotrophic lateral sclerosis (ALS), a common late-onset neurodegenerative disease, is associated with
fronto-temporal dementia (FTD) in 3–10% of patients. A mutation in CHMP2B was recently identified in a Danish pedigree
with autosomal dominant FTD. Subsequently, two unrelated patients with familial ALS, one of whom also showed features
of FTD, were shown to carry missense mutations in CHMP2B. The initial aim of this study was to determine whether
mutations in CHMP2B contribute more broadly to ALS pathogenesis.
Methodology/Principal Findings: Sequencing of CHMP2B in 433 ALS cases from the North of England identified 4 cases
carrying 3 missense mutations, including one novel mutation, p.Thr104Asn, none of which were present in 500
neurologically normal controls. Analysis of clinical and neuropathological data of these 4 cases showed a phenotype
consistent with the lower motor neuron predominant (progressive muscular atrophy (PMA)) variant of ALS. Only one had a
recognised family history of ALS and none had clinically apparent dementia. Microarray analysis of motor neurons from
CHMP2B cases, compared to controls, showed a distinct gene expression signature with significant differential expression
predicting disassembly of cell structure; increased calcium concentration in the ER lumen; decrease in the availability of ATP;
down-regulation of the classical and p38 MAPK signalling pathways, reduction in autophagy initiation and a global
repression of translation. Transfection of mutant CHMP2B into HEK-293 and COS-7 cells resulted in the formation of large
cytoplasmic vacuoles, aberrant lysosomal localisation demonstrated by CD63 staining and impairment of autophagy
indicated by increased levels of LC3-II protein. These changes were absent in control cells transfected with wild-type
CHMP2B.
Conclusions/Significance: We conclude that in a population drawn from North of England pathogenic CHMP2B mutations
are found in approximately 1% of cases of ALS and 10% of those with lower motor neuron predominant ALS. We provide a
body of evidence indicating the likely pathogenicity of the reported gene alterations. However, absolute confirmation of
pathogenicity requires further evidence, including documentation of familial transmission in ALS pedigrees which might be
most fruitfully explored in cases with a LMN predominant phenotype.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a late-onset, relentlessly
progressive and eventually fatal neurodegenerative disorder
characterised by the injury and death of upper motor neurons
(UMN) in the cortex and lower motor neurons (LMN) in the
brainstem and spinal cord [1]. The disorder comprises a range of
clinical phenotypes depending on the pathoanatomical distribu-
tion of the motor system degeneration. Classical ALS is a
combined UMN and LMN disorder. The pure LMN disorder of
progressive muscular atrophy (PMA) and the pure UMN disorder
of primary lateral sclerosis (PLS) share common molecular
pathology hallmarks with ALS, and are considered syndromic
variants. The majority of ALS cases are sporadic, although 5–10%
of cases are familial. Fifteen loci are known to be associated with
ALS, and eight causative genes have been identified, the most
common of which is SOD1 (Cu/Zn superoxide dismutase 1) [2].
Recently, we identified missense mutations in CHMP2B (charged
multivesicular protein 2B) in two individuals with familial ALS,
one of whom had associated features of frontotemporal dementia
(FTD) [3]. CHMP2B is expressed in all major areas of the human
brain, as well as multiple other tissues outside the CNS. Although
the exact function of CHMP2B is unknown, its yeast orthologue,
vacuolar protein sorting 2 (VPS2), is a component of the
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transport) [4]. ESCRTIII is an important component of the
multivesicular bodies (MVBs) sorting pathway, which plays a
critical role in the trafficking of proteins between the plasma
membrane, trans-Golgi network and vacuoles/lysosome [5].
Alterations to VPS2 in yeast results in the formation of dysmorphic
hybrid vacuole-endosome structures; additionally, disruption to
other ESCRTIII components abolishes the ability of MVBs to
internalise membrane-bound cargoes [5,6,7]. Interestingly, two
other MND-causing genes, ALS2 and ALS8, are proposed to
contribute to motor neuron injury by causing disruption to the
processes of endocytosis and vesicle trafficking [8,9,10,11].
Defects in CHMP2B were originally reported in a Danish
pedigree with autosomal dominant FTD [4]. The G.C single
nucleotide change in the acceptor splice site of exon 6 of CHMP2B
affected mRNA splicing, resulting in two aberrant transcripts:
inclusion of the 201-bp intronic sequence between exons 5 and 6
(CHMP2B
Intron5), or a short deletion of 10bp from the 59 end of
exon 6 (CHMP2B
D10). Expression of mutant CHMP2B protein in
cells resulted in aberrant structures dispersed throughout the
cytosol [4], and the ectopic expression of CHMP2B
Intron5 in cortical
neurons caused dendritic retraction prior to neurodegeneration
[12]. In addition, autophagosome accumulation and the inhibition
of autophagy have been seen in cells expressing the CHMP2B
mutations found in FTD [12,13].
Several neurodegenerative diseases are now believed to contain
an element of dysregulation of the lysosomal degradation of
proteins, as reviewed by Martinez-Vicente et al. [14]. The results
from these recent studies are part of a growing body of evidence
that common pathways are involved in a spectrum of neurode-
generative diseases [15]. It was recently discovered that the
ubiquitin positive inclusions seen in FTD and ALS contain the
same protein, TAR DNA-binding protein-43 (TDP43), and that
mutations in progranulin (PGRN) give rise to FTD with ubiquitin-
positive inclusion bodies similar to those seen in some ALS patients
[16,17]. It is proposed that mutations in CHMP2B may lead to
FTD and other neurodegenerative diseases, including ALS, which
is predicted to involve disruption to the cellular processes involved
in the recycling and degradation of proteins. However, the status
of CHMP2B mutations as a contributor to ALS has remained
uncertain, due to the lack of described pedigrees where mutations
segregate with disease in multiple affected individuals. The aims of
this study were i) to identify whether mutations in CHMP2B
contribute significantly to the pathogenesis of familial and
apparently sporadic ALS, by screening for genetic alterations in
a cohort of 433 ALS cases in whom the clinical phenotype had
been documented serially throughout the disease course; ii) to
investigate in CNS tissue changes in the gene expression profile of
motor neurons from cases with CHMP2B mutations compared to
neurologically normal controls, and iii) to investigate the functional
effects of CHMP2B mutations in an in vitro system. We propose that
CHMP2B missense mutations associate with ALS and demonstrate
that these mutations give rise to a distinct clinical and
neuropathological phenotype, cause a distinctive alteration in the
motor neuron transcriptome and disrupt cellular pathology,
compared to controls.
Methods
Patients and controls
DNA samples from 433 ALS cases were screened. Of these 37
had familial ALS (FALS) and were negative for mutations in
SOD1, TDP43, FUS/TLS, ANG and VAPB; 356 had classical
sporadic ALS with UMN and LMN clinical signs and 40 had ALS
with a LMN phenotype throughout the disease course (PMA
variant). Autopsy CNS tissue was available for 123 of the cases
screened and for all the patients in whom a mutation in CHMP2B
was found. DNA control samples (N=500) were obtained from
the Sheffield and Birmingham MND DNA banks and the
Newcastle Brain Tissue Resource. All control individuals were
neurologically normal and matched to the disease cohort by age
and sex. Approval for the use of DNA samples was obtained from
the South Sheffield Research Ethics Committee and written
consent was obtained from the donors. Ethnicity of cases and
controls was UK Caucasian.
PCR amplification and mutation screening of CHMP2B
DNA was extracted from snap frozen cerebellum or blood as
described previously [18]. PCR was performed as described in the
original CHMP2B publication [4]. Following clean-up with
ExoSAP-IT (GE Healthcare, UK), PCR products were bidirec-
tionally sequenced [18]. The CHMP2B nucleotide sequence was
taken from ENST00000263780 on the Ensembl database, and was
used to determine sites of known polymorphisms. Nucleotides
were numbered in accordance with the nomenclature recom-
mended by the Human Genome Variation Society (www.hgvs.
org).
To determine the prevalence of the c.311C.A change in the
control population, exon 3 PCR products were digested with the
restriction enzyme AccI, generating 244, 104 & 51bp fragments
from the wild type sequence. The C to A substitution abolishes a
restriction site, resulting in two fragments (244 & 155bp). The
c.618A.C change was screened by digestion of exon 6 PCR
products with BanI, which generated 207 & 96bp in the presence
of the substitution, whilst the wild type sequence of 303bp
remained uncut. The presence of c.-151C.A and c.85A.G in the
control population were determined by bidirectional sequencing of
exons 1 and 2, respectively.
Neuropathology
Brains and spinal cords were dissected so that one cerebral
hemisphere, the midbrain, left hemi-brainstem and left cerebellar
hemisphere were sliced for snap freezing. Selected spinal cord
segments were also snap frozen. The remaining tissues were fixed
in formalin for processing to paraffin wax and used in routine
staining and immunocytochemistry from all CNS levels. Standard
immunocytochemical methods, including antigen retrieval where
appropriate, were used to demonstrate localization of ubiquitin,
p62/sequestosome 1, TDP43, CD68 (a marker of microglial
activation), a-synuclein and AT8 (a tau marker) (Table 1). The
pathological survey reported here includes examination of cervical
and lumbar limb enlargements of the spinal cord, thoracic spinal
cord, multiple medulla oblongata and pontine levels to include
lower cranial motor nerve nuclei, upper pons and midbrain, the
hippocampus, motor cortex, frontal and temporal neocortex and
cerebellum.
Microarray analysis of cervical motor neurons from
CHMP2B cases vs. controls
Snap frozen cervical spinal cord was available for cases 1–3, but
not case 4, and the cervical cord from 7 control cases was used for
comparison. Ten micron sections were prepared, and 500 motor
neurons were isolated from each sample using laser-capture
microdissection (LCM); RNA was extracted as previously
described [19]. The quality (2100 bioanalyzer, RNA 6000 Pico
LabChip; Agilent, CA, USA) and quantity (NanoDrop 1000
spectrophotometer) of the RNA from all of the samples were
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Eberwine procedure [20] using the Two-cycle Amplification
Method (Affymetrix), and again checked for quality and quantity.
Fifteen micrograms of amplified cRNA from the 3 mutant
CHMP2B cases and 7 controls was fragmented and each
hybridised individually to 10 Human Genome U133 Plus 2.0
GeneChips (Affymetrix), as per manufacturer’s protocols. Follow-
ing stringency washes, chips were stained and scanned, and
GeneChip Operating Software (GCOS) used to produce signal
intensities for each transcript. ArrayAssist (Iobion Informatics, CA,
USA) was used to determine genes that showed significant
differential expression in the presence of CHMP2B mutations
compared to control samples. Transcripts were considered
differentially expressed if there was a twofold or greater difference
in the mean signal intensity of the CHMP2B cases compared to the
control group (p,0.05, two-tailed t test). Transcripts in which the
signal intensities on all 10 GeneChips were below 35 (the average
intensity of background noise level) were discarded as were those
transcripts of unknown function. The differentially expressed
transcripts on the resulting list were classified by biological process,
as determined by GeneOntology terms. To identify specific
pathways affected by CHMP2B mutations, PathwayArchitect
(Stratagene) and the DAVID Functional Annotation Tool
bioinformatics software packages were used [21].
Validation of microarray results by Q-PCR
Primers were designed and optimised to validate significant
changes in expression of genes with key roles in the pathways
affected by CHMP2B mutations (Table 2). Q-PCR was perfomed
using 25ng of cDNA, 16Brilliant II SYBR Green QPCR Master
Mix (Agilent, CA, USA), the optimised concentrations of forward
and reverse primers, and nuclease free water was used to make a
final reaction volume of 20ml. Samples were run on an Mx3000P
Real-Time PCR system (Stratagene) using previously published
parameters [19]. Gene expression values, normalised to actin
expression, were determined using the ddCt calculation [22].
Actin was selected as a housekeeping gene as its expression was
consistent across the 10 GeneChips. An unpaired two-tailed t test
was used to analyse the data and to determine the statistical
significance of any differences in gene expression (GraphPad Prism
5, Hearne Scientific Software).
In vitro models to investigate the functional effects of
CHMP2B mutations
HEK-293 cells (ECACC) were plated on 13mm coverslips in
Dulbecco’s Modified Eagle’s Medium ((DMEM) w Glucose + L-
glutamine, w/o Na pyruvate; Lonza) plus 10% fetal calf serum
(FCS, Biosera), in the absence of antibiotic (termed +/2). Cells
were transfected with 500ng myc-tagged CHMP2B with either
the wild-type, c.85A.G (p.I29V), c.311C.A (p.T104N) or
c.618A.C (p.Q206H) sequence, under a constitutive cytomega-
lovirus promoter, using Lipofectamine 2000 (Invitrogen) as per the
manufacturer’s protocol. After transfection, cells were grown in
DMEM plus 10% FCS for 24 hours. To investigate changes in the
lysosomal degradation pathway, autophagy was induced in
Table 1. Antibody source and conditions.
Antibody
(clone) Isotype Dilution Antigen retrieval Source
CD68 (PG-M1) IgG3 1:200 microwave 10min
citrate buffer
DAKO
Ubiquitin poly 1:200 microwave 10min
citrate buffer
DAKO
Tau (AT8) IgG1K microwave 10min
citrate buffer
Pierce Endogen
a-synuclein IgG 1:200 microwave 10min
citrate buffer
Zymed
p62/
sequestosome
poly 1:200 microwave 10min
citrate buffer
Progen
doi:10.1371/journal.pone.0009872.t001
Table 2. Primer sequences for Q-PCR validation of selected genes.
Gene name Primer name Primer sequence Concentration (nM)
Tubulin, beta TUBB-F 59-GTCACCTTCATTGGCAATAGCA-39 900
TUBB-R 59-GCGGAACATGGCAGTGAACT-39 600
Microtubule-associated protein 4 MAP4-F 59-GGACCAGCTTTCCTCCGTAGA-39 900
MAP4R 59-GACTACGCAACCCTGTTTCCTT-3 600
Autophagy gene 1 ATG1-F 59-CGCCACATAACAGACAAAAATACAC-39 900
ATG1-R 59-CCCCACAAGGTGAGAATAAAGC-39 900
Kinesin family member 1A KIF1A-F 59-GAGAGTCTGGTCATAGGAGTCATGTC-39 600
KIF1A-R 59-GGCTACTGTCTTTCCTTGAGCTAAA-39 600
Na+/Ca2+ exchanger NCX1-F 59-TTATAGAGACGTTGATATGTTGGATGTG-39 600
NCX1-R 59-ACAGTGCAGATGTGAAATAAATACTTTG-39 300
Sarcoplasmic/endoplasmic
reticulum calcium ATPase 2
SERCA-F 59-TGGAGTAACCGCTTCCTAAACC-39 900
SERCA-R 59-TACTTTTCTTTTTCCCCAACATCAG-39 900
E2F Transcription factor 6 E2F6-F 59-GCGGAAAAGTCTGAGCTGTGTAGT-39 600
E2F2-R 59-GACCTCTCCTACTCTTGTGGCTTAA-39 600
Cadherin 13 CDH13-F 59-GCCAAGAAAAGGGCTGACATT-39 600
CDH13-R 59-GTGTCCCCATTAGAATCAGTACGA-39 600
doi:10.1371/journal.pone.0009872.t002
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transfection. Cells are subsequently referred to as +/2 (10% FCS,
no antibiotic) or 2/2 (no FCS for the last 2 hours of growth post-
transfection, no antibiotic). Cells were fixed, (4% paraformalde-
hyde (Sigma)), permeabilised (0.1% triton (Sigma)), and blocked in
5% goat serum (Sigma) in PBS for one hour. Primary antibodies
were mouse a-CD63 (in-house), a marker of late-endosomes and
lysosomes, and either rabbit or mouse a-myc (AbCam). Secondary
antibodies were anti-mouse or a-rabbit AlexaFluor488 and a-
mouse or a-rabbit AlexaFluor555 (Molecular Probes). Cells were
visualised using the Zeiss Axioplan2 microscope and the Zeiss
LSM 510 confocal microscope. Transfected cells were scored for
the presence of vacuoles and halos. To measure vacuole area,
images were captured from a minimum of 25 fields of view per
transfection round. ImageJ was used to convert the images to
greyscale, subtract the background and adjust the threshold. The
‘analyse particles’ plug-in was used to measure the area of the
vacuoles in mm
2.
COS-7 cells (ECACC) were plated in 6 well tissue culture plates
in DMEM, plus 10% FCS, in the absence of antibiotic 24 hours
prior to transfection (DMEM+/2). Cells were transfected with
2mg of plasmid DNA, as described above, using Lipofectamine
2000 as per the manufacturer’s protocol. To induce autophagy,
22 hours post-transfection cells were serum starved for 2 hours,
before being washed in PBS and collected in 500ml1 6Trypsin-
EDTA (TE). An equal volume of DMEM+/2 was added to the
cells to quench the TE, and cells were pelleted by spinning at
3,0006g for 2 minutes. Cells were washed with 500ml PBS and
spun again to re-pellet. The supernatant was discarded and cells
were resuspended in 40ml of lysis buffer (25mM Tris pH7.4, 0.5%
(v/v) Triton, 50mM NaCl, 2mM EDTA, plus protease inhibitor
cocktail) and lysed at 4uC. Protein concentration was estimated
using a Bradford assay, and 20mg of total protein per sample was
separated by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) (12% acrylamide gels) and transferred to
PVDF membranes. Blots were blocked in TBS-T (20mM Tris-
HCl pH7.6, 137mM NaCl, plus 0.1% (v/v) Tween-20) and 5%
(w/v) dried skimmed milk. They were then probed with rabbit
polyclonal anti-LC3 (Stratech) diluted 1:1000 and rabbit poly-
clonal anti-actin diluted 1:1000 (used as a protein loading control)
in TBS-T plus milk for one hour at room temperature, followed
by peroxidase-conjugated secondary antibody (1:4000, one hour
at room temperature). Antibody binding was revealed
using enhanced chemiluminescence, as per the manufacturer’s
instructions.
Results
Mutation screening of CHMP2B in ALS patients
Sequence analysis of the entire coding region and intron/exon
boundaries of CHMP2B from 433 ALS cases identified point
mutations in four cases (0.9%) (Figure 1). One patient (Case 1) was
heterozygous for a previously undescribed mutation, a single
nucleotide substitution, c.311C.A, which results in the substitu-
tion of threonine by asparagine (p.T104N). Two subjects (Cases 2
& 3), were heterozygous for a c.85A.G substitution, resulting in a
previously described isoleucine to valine substitution (p.I29V). The
fourth patient (Case 4) was the previously published glutamine to
histidine (c.618A.C, p.Q206H) case [3]. These mutations are all
highly conserved in mammals, with the p.T104N and p.Q206H
also conserved in chicken and zebrafish (see Figure S1). The
c.311C.A, c.85A.G and c.618A.C changes were absent in
1000 control chromosomes from 500 neurologically normal
individuals. The c.618A.C mutation has previously been shown
Figure 1. Chromatograms showing nucleotide changes in CHMP2B. On the left side of each image is the normal wild-type sequence, whilst
the right side shows the nucleotide change for each of the changes identified in CHMP2B.
doi:10.1371/journal.pone.0009872.g001
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c.-151C.A, was also identified in the 59UTR of CHMP2B in four
cases (0.9%), however, this change was also present in 2% of
controls.
Clinical phenotypes of patients carrying mutations in
CHMP2B
In all cases neurological investigations including haematological
and biochemical blood tests, CSF analysis, neuroimaging and
neurophysiological evaluation were compatible with a diagnosis of
ALS. None of the cases presented with or developed signs of
frontotemporal dementia (FTD).
Case 1 was a 54 year old man who presented with respiratory
failure and bulbar dysfunction. His first problem was dyspnoea
whilst swimming. He was treated with non-invasive ventilation
(NIV) from the time of diagnosis throughout his illness. There was
no reported family history of neurological disease. On examination
at the time of presentation, he had a moderately severe dysarthria
and bilateral wasting, fasciculation and weakness of the tongue. He
had wasting and proximal fasciculation in the upper and lower
limbs, weakness of the ulnar and median innervated intrinsic hand
muscles and the hip flexors. The deep tendon reflexes were normal
and plantar responses were flexor, consistent with a pure lower
motor neuron phenotype. His symptoms progressed rapidly over
the course of 15 months, at which stage he died of respiratory
failure with relatively preserved limb function.
Case 2 was a 64 year old female who presented with back pain
and progressive weakness of the right leg. She underwent L4/5
spinal decompression to no avail and her symptoms continued to
progress to affect both legs, with later development of upper limb,
bulbar and respiratory muscle weakness. There was no significant
family history. On examination she had wasting and predomi-
nantly distal weakness in the lower limbs with upper limb
fasciculations. The reflexes were normal throughout, and the
plantar reflexes were flexor. She died 66 months after symptom
onset.
Case 3 was a 49 year old man who initially noticed a
deterioration in his ability to play football, due to weakness
affecting his left leg. His symptoms progressed steadily. Fifteen
months after onset he had wasting and fasciculations in the upper
limbs with preserved power. The lower limbs were wasted
globally, most severely in the left anterior tibial compartment.
Power in hip flexion and ankle dorsiflexion was reduced on the left
and the ankle jerks were absent bilaterally. He developed bulbar
symptoms 24 months after disease onset. No UMN signs were
detectable clinically throughout the disease course. There was no
family history of ALS, with healthy parents and 5 siblings,
including one with developmental delay described as possible
autism. He died of respiratory failure 29 months after his initial
symptom onset.
Case 4 was a 73 year old male who presented with dysarthria,
dysphagia and clumsiness of the hands. His symptoms progressed
rapidly and 12 months after onset he had a wasted, fasciculating
tongue, LMN weakness in the upper and lower limbs, depressed
reflexes and flexor plantar responses. He died 14 months after
disease onset. He had a cousin who had died from ALS several
years earlier.
Neuropathological findings in the four cases with
CHMP2B mutations
The anatomical and molecular pathology of all four cases was
similar and corresponded to a rather stereotypical pattern of LMN
predominant degeneration (Figure 2). Involvement of UMNs was
not detectable in conventional stains and the Betz cell somata were
readily identified and appeared normal in all cases. There was no
evidence of myelin pallor in the corticospinal tracts (Figure 2a)
other than equivocal changes in the medullary pyramid of one
case (Case 1), which was not present in the spinal cord at any level.
Microglial activation demonstrated by CD68 staining is a more
sensitive indication of early white matter tract degeneration [23].
Three of the cases showed no evidence for corticospinal tract
degeneration at any level. One case (Case 1) showed marked
subcortical microglial activation centred on the precentral gyrus,
mild changes in the medulla and only equivocal changes in the
spinal cord white matter. Glial pathology was previously reported
in the motor cortex in case 4, comprising oligodendroglial coiled
bodies immunoreactive for p62 and TDP43, which were not
readily demonstrated by conventional ubiquitin immunocyto-
chemistry [3]. These lesions were present in the motor cortex and
the ventral horns of all the cases. These lesions are not confined to
CHMP2B-related ALS as previously reported [3], but are
consistently present to a variable degree in sporadic and non-
SOD1-related familial variants of ALS [24].
The LMN pathology in all cases was typical of the primary
muscular atrophy (PMA) variant of ALS. There was variable
severe loss of motor neurons from all spinal levels. Bulbar motor
nuclei were generally less severely affected. Surviving motor
neurons contained a population of inclusion bodies demonstrated
by ubiquitin, p62 and TDP43 staining. In three cases these were
exclusively of ‘compact’ morphology with no demonstrable ‘skeins’
(Figures 2d,g,h, i). All the glia and neurones containing TDP43
intracytoplasmic inclusions showed decreased staining in the cell
nucleus in comparison to retention of normal nuclear staining in
cells negative for inclusions. One case showed very few
intraneuronal lesions, in the context of massive motor neuronal
loss, of rather indeterminate morphology. Bunina bodies were
absent from all the cases. Extramotor involvement of the CNS
assessed by p62/TDP43 immunoreactive lesions was absent
including evaluation of the hippocampal dentate granule cells
and the frontal and temporal neocortex. Staining for related
neurodegenerative pathologies (tau and alpha-synuclein) showed
minimal expression of Alzheimer’s disease pathology (low Braak
stage and minimal cortical amyloid deposition) and absence of
synucleinopathy.
Gene expression profiling of motor neurons from
CHMP2B cases compared to controls
The percentage of genes described as present on the 10
GeneChips was an average of 22.7% for the three available
CHMP2B cases (26 p.I29V, 16 p.T104N), and 28.2% for the
seven neurologically normal control cases. (CEL files for each of
the 10 GeneChips have been submitted to the Gene Expression
Omnibus Repository, Accession GSE19332). ArrayAssist (Affyme-
trix) was used to analyse expression data. Duplicate probes were
removed, as were probes for unknown genes, and those for which
the signal intensity in all 10 GeneChips was below 35 (the average
background level). After filtering, 890 genes were found to be
downregulated, and 555 upregulated, all with a fold change $2,
and p value #0.05. These 1,445 differentially expressed genes
were then categorised according to their biological process, as
defined by GeneOntology terms (Table 3) (Full list available in
Table S1). An additional 398 genes were downregulated and 358
upregulated at a fold change of 1.5–1.99, p#0.05. These were
only considered if they were involved in the pathways of interest.
The functional annotation tool of the DAVID Bioinformatics
Resource was used to identify pathways with a significant number
of differentially expressed genes, namely: axon guidance, regula-
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transport, mammalian target of rapamycin (mTOR) signalling and
regulation of autophagy, mitogen activated kinase (MAPK)
signalling, calcium signalling, and cell cycle and apoptosis
(Table 4). We focused our analysis on pathways that were of most
biological interest in relation to the predicted function of
CHMP2B and related proteins.
Regulation of actin cytoskeleton and SNARE interactions
in vesicular transport (Figure 3). Microtubule-associated
protein 1s (MAP1S) and 4 (MAP4), are involved in microtubule
(MT) stabilisation [25], and are both downregulated (Y2.8 and Y3,
respectively), whereas the MT-destabilising protein stathmin
(STMN1), is upregulated (X1.6) in the presence of mutant
CHMP2B. Microtubule destabilisation may result in transport
impairment, and this is supported by downregulation of several
kinesin (KIF1A Y3, KIF5C Y2.8 and KIF1C Y2.2) and dynein
transcripts (DYNLRB1 Y2.8, DYNLL2 Y3 and DYNC1H1 Y3.5). In
addition, both tubulin alpha and beta, main components of
microtubules, are highly downregulated (TUBA Y4.5, TUBB Y5),
probably in response to destabilising stimuli. The transcript for
Golgi apparatus protein 1 (GLG1), used as a marker to assess Golgi
apparatus (GA) structure and function, is highly downregulated
(Y3.16) in CHMP2B motor neurons, as are other structural
proteins: Golgi reassembly stacking protein 1 (GORASP1 Y3.7)
and components of the oligomeric Golgi complex 2 and 7 (COG2
Y1.5 and COG7 Y2.6).
Fusion of ER-derived vesicles with the Golgi requires the
pairing of the v-SNARE, blocked early in transport 1 (BET1), with
its t-SNARE complex comprising syntaxin 5 (STX5), Golgi SNAP
receptor complex member 2 (GOSR2;X2.76) and SEC22A, B (X1.6),
C. SEC23 and SEC24, whose function is to coat the vesicles
travelling along microtubules to the cis-Golgi, are also upregulated
(X1.5 and X1.8 respectively). In contrast, USE1 (unconventional
SNARE in the ER homologue 1), which is involved in retrograde
transport from the Golgi to the ER [26], is downregulated (Y2.66).
Furthermore, two components of the coatomer protein complex I,
COPE and COPZ1 are downregulated (Y3.8 and Y3 respectively).
This complex is responsible for coating of the vesicles travelling
between ER and Golgi. Also downregulated are the t-SNAREs,
VTI1 (Y2.9) and STX4 (Y2.2), which encode proteins involved in
vesicle docking and transport from the GA to the endosome. In
addition, many of the adaptor-related protein complex transcripts
are strongly downregulated, AP1B1 (Y2.29), AP2A2 (Y2.25), AP2S1
(Y3.35), AP3D1 (Y2.67) and AP4B1 (Y2), and these also play a key
role in the transport of vesicles from the GA to the endosomal
sorting pathway. KIF1A, TUBB and MAP4 were selected for
Figure 2. Photomicrography of pathological changes associated with CHMP2B mutations. In all cases there was no evidence of myelin
pallor affecting the corticospinal tracts (a). Case 1 showed some minor upregulation of CD68 immunoreactivity in the spinal lateral corticospinal
tracts (b) compared with the dorsal columns (c). Sequestosome 1/p62 staining showed compact intraneuronal inclusions in spinal motor neurons and
occasional glial inclusions (d). The glial inclusions show coiled body morphology immunoreactive for both TDP43 (e) and p62 (f). All cases showed a
predominance of compact intraneuronal inclusions in motor neurons (g–i). (a: Luxol fast blue; b,c: CD68; d,f,h,i: p62; e,g: TDP43. Microscopy at62 obj.
(a); 610 obj. (b,c); 640 obj. (d–i)).
doi:10.1371/journal.pone.0009872.g002
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downregulated by 2.96 (p=0.0009), 3.07 (p,0.0001) and 3.52
fold (p=0.0003), respectively (Table 5).
mTOR signalling and regulation of autophagy
(Figure 3). mTOR is a serine/threonine protein kinase that
integrates the input from multiple upstream pathways, and whose
activity is stimulated by insulin, growth factors, serum,
phosphatidic acid, amino acids and oxidative stress [27,28].
mTOR associates with several other proteins: Raptor, GbL and
PRAS40, to form a complex known as mTORC1 [29]. mTOR is
involved in many cellular processes, one of which is the inhibition
of autophagy. Importantly, a key protein involved in autophagy
activation, ATG1, is strongly downregulated (Y3.48). ATG1 is
essential for the formation of vesicles at the phagophore assembly
site (PAS) [30], suggesting autophagy is impaired in CHMP2B
motor neurons. In addition to its role in autophagy inhibition, the
mTOR signalling pathway is involved in translation initiation.
mTORC1 inhibits PP2A (protein phosphatase 2A), of which the
regulatory subunit 4 is downregulated (Y2.03). PP2A inhibits
p70S6K, which binds to the eukaryotic translation initiation factor
3 (eIF3) when inactive [31]. Activation of p70S6K by mTORC1
causes it to release eIF3, allowing p70S6K to activate target
proteins [31]. eIF3 consists of twelve non-identical subunits (eIF3
A(Y2.03), B(Y3.97), C(3.23Y), D(Y2.28), E, F, G(Y1.80), H, I(Y5.79),
J, K and L) [32]. Upon release from p70S6K, eIF3 binds to
ribosomal protein S6 (RPS6, Y2.28), which is part of the 40S
ribosome subunit [33]. The eIF3/40S complex then forms a larger
pre-initiation complex with eIF4E, eIF4G, eIF4B (Y1.94) and eIFA
(Y3.04). eIF4A plays a role in resolving 59UTR mRNA secondary
structure, and thus allowing the ribosome to bind, and this helicase
action is facilitated by eIF4B [34]. ATG1 was selected for Q-PCR
verification, and was downregulated 2.2 fold, p=0.003 (Table 5).
MAPK signalling (Figure 4). There are two main pathways
through which MAP kinases signal: the classical MAPK pathway
and the p38 MAP kinase pathway [35]. The first step in the
activation of classical MAPK signalling is ligand binding to a
receptor tyrosine kinase. The phosphorylated tyrosine of the target
protein is bound by the SH2 domain of GRB2, which also
contains an SH3 domain that binds to the proline-rich region of
SOS. Once bound by GRB2, SOS catalyses the substitution of
GDP to GTP on RAS (Y4.96). GTP-bound RAS activates the
MAPKKK, RAF1 (Y2.10), by phosphorylation. RAF1 subse-
quently phosphorylates the MAPKKs, MEK1/2, which in turn
activate the MAP kinases ERK1 and ERK2 (Y1.71). MAPK
interacting serine/threonine 2 (MKNK2) is directly activated by
ERK, and is itself downregulated (Y3.24). MKNK2 contributes to
the basal phosphorylation of eIF4A, which is essential for
translation initiation [36]. Downregulation of these core pathway
components suggests repression of the basal response to growth
factors, an effect that appears to be amplified by upregulation of
the Ras inhibitor, NF1 (X1.81) and the ERK1/2 inhibitor,
PTPN5, (X1.59).
Activation of p38 is mediated by multiple upstream kinases and
this pathway plays a key role in the cell’s stress response as well as
the phosphorylation of multiple target proteins including phos-
pholipase A2 and MAP tau. TAK1 (Y2.42) is an upstream kinase
that phosphorylates MAPK kinases 3 and 6 (MEK3, 6), which
subsequently phosphorylate p38 (Y5.34). There is strong down-
Table 3. Grouping of 891 downregulated and 556 upregulated genes, with a fold change (FC) $2, and p value #0.05, into their
biological process, as defined by GeneOntology terms.
Number of genes FC $2, p#0.05 Number of genes FC $2, p#0.05
Biological process Downregulated Upregulated
Apoptosis 16 9
Cell adhesion 34 16
Cell cycle 49 24
Cell motility 10 1
Cytoskeleton 23 17
Development 8 13
Immune response 18 29
Ion transport 20 29
Kinases/phosphatases 19 8
Metabolism 88 36
Protein cleavage/degradation 41 32
Protein folding 5 2
Protein modification 25 15
RNA processing 32 19
Signalling 55 64
Stress response 13 6
Transcription 84 76
Translation 56 7
Transport 77 35
Miscellaneous 101 49
Unknown 118 69
doi:10.1371/journal.pone.0009872.t003
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axon guidance, cell cycle and apoptosis, regulation of actin
cytoskeleton and SNARE interactions in vesicular transport,
and mTOR signalling and regulation of autophagy in CHMP2B
motor neurons compared to neurologically normal controls.
Pathway/Probe ID
Gene
symbol
Fold
change
Calcium signalling pathway
1559633_a_at CHRM3 2.92
211426_x_at Gq 23.08
204248_at Gq11 22.51
240052_at IP3R 21.93
235518_at NCX 3.21
212826_s_at ANT3 21.82
208844_at VDAC3 2.93
216033_s_at FYR 22.88
209186_at SERCA 2.12
MAPK signalling pathway
1560689_s_at AKT 1.87
1552264_a_at ERK2 21.71
201841_s_at HSP27 212.85
215050_x_at MK2 21.6
223199_at MNK2 23.24
210631_at NF1 1.81
211561_x_at p38 25.24
224411_at PLA2G12B 2.58
233470_at PTPN5 1.59
201244_s_at RAF1 22.1
212647_at RAS 24.96
217714_x_at STMN1 1.6
211537_x_at TAK1 22.42
Axon guidance
1562240_at PLXNA4A 2.32
229026_at CDC42SE2 3.38
235412_at ARHGEF7 4.37
208009_s_at ARHGEF16 2
226576_at ARHGAP26 22.39
230803_s_at ARHGAP24 23.9
212647_at RRAS 24.96
206281_at ADCYAP1 29.4
217480_x_at NTN2L 2.67
210083_at SEMA7A 1.82
211651_s_at LAMB1 23.81
216840_s_at LAMA2 23.86
203071_at SEMA3B 25.39
216837_at EPHA5 2.35
206070_s_at EPHA3 23.31
Cell cycle & apoptosis
212312_at BCL2L1 22.37
208876_s_at PAK2 2.92
209364_at BAD 23.92
228361_at E2F2 2.73
231237_x_at E2F5 6.93
Pathway/Probe ID
Gene
symbol
Fold
change
203957_at E2F6 2.8
229468_at CDK3 1.89
1561190_at CDKL3 3.14
208656_s_at CCNI 22.03
231198_at CDK6 22.15
205899_at CCNA1 22.24
1555411_a_at CCNL1 23.29
208711_s_at CCND1 25.88
212983_at HRAS 22.71
201244_s_at RAF1 22.1
211561_x_at p38 25.24
1552264_a_at ERK1 21.71
201202_at PCNA 22.68
207574_s_at GADD45B 22.44
Regulation of actin cytoskeleton & SNARE
interactions in vesicular transport
209244_s_at KIF1C 22.22
203129_s_at KIF5C 22.8
203849_s_at KIF1A 23.02
217917_s_at DYNLRB1 22.8
229106_at DYNLL2 22.99
229115_at DYNC1H1 23.54
218522_s_at MAP1S 22.83
212567_s_at MAP4 23.1
217714_x_at STMN1 1.6
212639_x_at TUBA1B 23.98
216323_x_at TUBA3D 23.33
210527_x_at TUBA3C 23.55
213646_x_at TUBA1B 24.48
211750_x_at TUBA1C 23.94
202154_x_at TUBB3 24.13
209026_x_at TUBB 24.87
208977_x_at TUBB2C 25.18
mTOR signalling and regulation of autophagy
200709_at FKBP12 21.79
209333_at ATG1 23.48
201254_x_at RPS6 22.28
216105_x_at PP2A 22.03
211787_s_at EIF4A1 23.04
211937_at EIF4B 21.93
200596_s_at EIF3A 22.03
203462_x_at EIF3B 23.97
200647_x_at EIF3C 23.3
200005_at EIF3D 22.28
208887_at EIF3G 21.8
208756_at EIF3I 25.79
(Fold change: positive numbers indicate upregulated, whilst negative numbers
depict downregulated transcripts).
doi:10.1371/journal.pone.0009872.t004
Table 4. Cont.
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strengthened by upregulation of the p38 (and ERK1/2) inhibitor
PTPN5 (X1.59). Additionally, the p38 target, MK2 is downreg-
ulated (Y1.60), which plays a role in the regulation of mRNA
stability and the reorganisation of actin [35]. MK2 activates
Hsp27 (Y12.85), which binds to and inactivates the pro-apoptotic
molecules caspase-3, caspase-9 and cytochrome c [37].
Calcium signalling (Figure 5). The G protein coupled
receptor, cholinergic receptor, muscarinic 3 (CHRM3), is
upregulated (X2.92) in CHMP2B mutant motor neurons.
Muscarinic3 (M3) receptors couple to phospholipase Cb (PLCb)
via the Gq class a-subunits [38]. However, as both Gq and Gq11 are
downregulated (Y3.08 and Y2.51, repectively), this would predict a
decrease in PLCb activation, despite the increase in CHRM3
transcription. PLCb functions by catalysing the hydrolysis of
phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to the IP3
receptor (IP3R, Y1.93), which is located on the ER membrane,
resulting in the opening of a IP3-gated Ca
2+-release channel, thus
allowing calcium to exit the ER lumen and enter the cytoplasm,
where it can propagate the signal by activating protein kinase C
(PKC). Following depletion of ER stores, calcium is re-
accumulated through sarco-endoplasmic Ca
2+ ATPase (SERCA,
X2.12), which is directly controlled by the ATP supplied by
mitochondria [39]. ANT3 catalyses the exchange of ATP for ADP
from the mitochondrial matrix through the inner mitochondrial
membrane into the inter-membrane space, and is downregulated
(Y1.82). Solute carrier family 8, sodium/calcium exchanger 1
Figure 3. Summary of key gene expression changes to ER and Golgi function, vesicular transport, mTOR signalling and autophagy.
The downregulation of multiple transcripts encoding ribosomal proteins, translation initiation factors (eIFs) and the ribosomal subunit, RPS6 suggests
a global repression of translation within the cell (1). SEC23 and SEC24 coat vesicles into which immature proteins are packaged and are upregulated.
Vesicles are transported along microtubules (MTs) from the ER-Golgi intermediate compartment; however, downregulation of the main components
of microtubules, TUBA and TUBB, and the MT-stabilising proteins, MAP1S and MAP4, indicates MT disassembly and therefore disruption to vesicular
transport (2). This is enhanced by upregulation of STMN1, a MT-destabilising protein, whose over-expression has also been demonstrated to result in
Golgi fragmentation. Downregulation of transcripts maintaining Golgi structure (GLG1, GORASP1, COG2 and COG7) support the hypothesis of Golgi
fragmentation (3). COPI is used to coat empty vesicles exiting the Golgi for recycling back to the ER, however, two main constituents, COPE and
COPZ1, are downregulated, as is USE1, which is required for vesicle fusion with the ER. These findings predict an eventual deficit of material available
to ER for the packaging of newly synthesised proteins (4). There is dysregulation of multiple SNARE transcripts, which are required for vesicle fusion.
BOS1 and SEC22 are upregulated, which may be the Golgi’s response to the reduction in vesicles being transported along destabilised microtubules.
Multiple SNAREs and adaptor proteins (VTI1, STX4, AP1B1, AP2A2, AP2S1, AP3D1 and AP4B1), which are required for fusion between vesicles carrying
mature proteins and the cell surface, endosomes and lysosomes, are downregulated, predicting impairment in the delivery of proteins throughout
the cell (5). Finally, inhibition of autophagy by the mTORC1 complex and downregulation of ATG1, which forms the phagophore assembly site (PAS)
with ATG17 and ATG13 to initiate autophagy, indicates a decrease in the clearance of cellular debris which may result in cytosolic accumulations and
contribute to motor neuron injury (6).
doi:10.1371/journal.pone.0009872.g003
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X2.93), are located on the inner mitochondrial membrane and
outer mitochondrial membrane, respectively, and pump calcium
out of the mitochondrial matrix and into the cytoplasm, where it is
transported to the ER lumen via SERCA [39]. NCX1 and SERCA
were selected for verification by Q-PCR, and were found to be
upregulated by 25.75 fold (p,0.0001) and 1.66 fold (p=0.0044),
respectively (Table 5).
We additionally validated E2F transcription factor (E2F6) and
cadherin 13 (CDH13) by Q-PCR. These genes had microarray
fold changes of 2.80 and 5.66, respectively, and Q-PCR fold
changes of 3.54 (p=0.0112) and 10.43 (p=0.0038), respectively
(Table 5).
Cellular pathology of CHMP2B mutations
To identify pathogenic effects of CHMP2B mutations, HEK-293
cells were transfected with constructs containing myc-tagged full-
length CHMP2B with either wild-type or p.I29V, p.T104N or
p.Q206H mutant CHMP2B. 24 hours after transfection, cells
expressing wild-type CHMP2B showed a typically diffuse pattern
of staining throughout the cell (Figure 6A). Cells expressing mutant
CHMP2B isoforms had large cytoplasmic vacuoles that were
devoid of lumenal staining for the recombinant protein, such
vacuoles were rarely seen in cells expressing wild-type protein
Table 5. Comparison of fold-changes calculated by
microarray experiments and determined by Q-PCR.
Gene Microarray fold change Q-PCR fold change (p value)
MAP4 23 23.52 (p=0.0003)
TUBB 24.87 23.07 (p,0.0001)
ATG1 23.48 22.2 (p=0.003)
KIF1A 23.02 22.96 (p=0.0009)
NCX1 3.21 25.8 (p,0.0001)
SERCA 2.12 1.66 (p=0.0044)
E2F6 2.80 3.54 (p=0.0112)
CDH13 5.66 10.43 (p=0.0038)
The p value for the Q-PCR was calculated using an unpaired t test.
doi:10.1371/journal.pone.0009872.t005
Figure 4. Defects in MAPK signalling as a result of mutations in CHMP2B. There are two main pathways through which MAP kinases signal:
the classical MAPK pathway and the p38 MAP kinase pathway. In the classical signalling pathway, ligand binding results in receptor activation, which
in turns leads to the activation of GRB2 and SOS. SOS catalyses the substitution of GDP for GTP on RAS (Y), which then activates RAF1 (Y). RAF1
subsequently phosphorylates MEK1/2, which in turn activate ERK1 and ERK2 (Y). The ERK proteins activate MKNK2 (Y), which is directly responsible for
activation of proteins required for translation initiation. Downregulation of multiple core signalling components in combination with upregulation of
the inhibitors, NF1 and PTPN5 predicts inability of the cell’s basal response to growth factors. The p38 MAPK pathway is a signalling cascade that is
distinct, but not exclusive from the classical MAPK signalling pathway. As with the classical MAPK pathway, multiple elements of the pathway are
downregulated: TAK1(Y), p38 (Y), MK2 (Y) and HSP27 (Y) which may result in a decrease in mRNA stability and the cell’s anti-apoptotic response.
(PM=plasma membrane)
doi:10.1371/journal.pone.0009872.g004
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more vacuoles with an area greater than 1mm
2 in cells expressing
mutant CHMP2B protein compared to wild-type (one way
ANOVA: p,0.0001, Figure 7). Additionally, the presence of
mutant CHMP2B increased the number of cells with vacuoles
greater than 1mm
2 in area (Bonferroni post-test, p,0.001), as did
serum withdrawal (Bonferroni post-test, p,0.0001). A second
phenotype observed in the mutant cells was the presence of
vacuoles with an accumulation of CHMP2B mutant protein on
the outer membrane, termed halos (Figure 6E). The number of
cells with halos in cells expressing the p.T104N isoform of
CHMP2B was significantly increased (Bonferroni post-test,
p,0.05). When cells were deprived of serum the presence of
halos was even more striking in mutant cells. Co-staining with
CD63, a tetraspanin that is abundant in late endosomes and
lysosomes, revealed an interesting change in staining pattern in
cells expressing mutant CHMP2B. In cells expressing WT
CHMP2B, CD63 co-localises with small vacuoles within the
cytoplasm (Figure 6F–H). In cells expressing mutant CHMP2B,
CD63 does not co-localise with the large cytoplasmic vacuoles
caused by mutant CHMP2B transfection, but instead is found on
the membrane of these aberrant structures (Figure 6 I–K).
Immunoblotting of LC3 typically reveals two bands, LC3-I
(18kDa) and LC3-II (16kDa). During the formation of autophago-
somes, the cytoplasmic form of LC3 (LC3-I) is recruited, where it
undergoes site-specific proteolysis and lipidation, generating LC3-
II which sequesters to the membrane of the autophagosomes [40].
The level of LC3-II can be used to monitor autophagic activity, as
it correlates with the number of autophagosomes. Western blotting
for LC3 in COS-7 cells showed a significant increase in LC3-II
levels in cells expressing mutant CHMP2B compared to those
expressing wild-type protein (Figure 8).
Discussion
In our cohort, we have identified mutations in CHMP2B in four
out of 433 individuals with ALS, giving a frequency of just less
than 1%. This is approximately half of the frequency of SOD1
mutations, which have been reported to account for approxi-
mately 20% of familial ALS cases [41], and 2% of all ALS cases
[42,43,44]. Of note, only 1 of our 4 cases of CHMP2B associated
ALS/MND had a discernible family history compatible with ALS
in a second-degree relative. This supports the hypothesis that some
apparently sporadic ALS cases have a genetic component.
Evidence from a UK twin study, which examined concordance
in both mono- and dizygotic twins (having first excluded probands
from families in which dominant inheritance of MND had already
been identified), estimated the heritability of ALS to be between
0.38 and 0.85; indicating that genetic factors are likely to make a
substantial contribution to the sporadic form of the disease [45].
Although the present study has not been able to document the
segregation of CHMP2B in multiple affected members of specific
pedigrees in ALS, we believe our results support the body of
evidence for the contribution of genetic factors to apparently
sporadic ALS.
All 4 cases in this report were negative for changes in SOD1,
ANG, TDP43, VAPB and FUS/TLS. Clinically, all four cases
presented with a phenotype consistent with a lower motor neuron
phenotype of ALS. In this cohort only 40 cases are recorded
clinically as having a lower motor neuron predominant phenotype
and CHMP2B mutations were found in 4 (10%) of these cases. In
our autopsy cohort, 15/123 cases had a LMN phenotype
pathologically. Of these 15, three lack any evidence of ubiqui-
tin/TDP43 neuronal inclusion pathology, one in the presence of a
mitochondrial transfer RNA gene mutation [46], and another as
one of a pair of brothers with MND and colonic neoplasia recently
found to have a mutation in FUS/TLS [47]. As such CHMP2B-
related ALS is highly over-represented in this LMN predominant
clinical subgroup. It is interesting to note that although mutations
in CHMP2B were originally identified in patients with FTD, none
of the four cases we identified had clinically apparent cognitive
changes and there were no noteworthy pathological changes in the
hippocampus.
A previous report of 166 familial and 372 sporadic ‘‘classical’’
ALS cases of predominantly Anglo-Celtic origin from Australia
and London found no evidence of mutations in CHMP2B [48].
However, population differences in other ALS pathogenic
mutations have been previously reported as exemplified by the
lack of TARDBP mutations in some populations and [49,50] the
Figure 5. Defects in calcium signalling as a result of CHMP2B
mutations. Downregulation of the a-subunits, Gq (Y) and Gq11 (Y)
indicates a decrease in PLCb activation, despite upregulation of the
cholinergic receptor CHRM3 (X). A decrease in PLCb activity would
reduce the amount of phosphatidylinositol 4,5-bisphosphate (PIP2)
hydrolysed to inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG).
Combining the decrease in IP3, with downregulation of its receptor,
IP3R (Y), would reduce the opening of a Ca
2+-release channel on the ER
membrane, which allows Ca
2+ to exit the ER lumen into the cytosol.
SERCA, which pumps Ca
2+ out of the cytoplasm into the ER lumen is
upregulated, so these findings predict an increased Ca
2+ concentration
in the ER lumen. Upregulation of NCX1(X)a n dV D A C 3 ( X), and
downregulation of ANT3(Y), predict that mitochondria are increasing
the amount of calcium pumped out of the matrix, but decreasing the
amount of ATP leaving the organelle. Amplifying the aberrant
intracellular calcium levels, in addition to reducing the amount of
energy available for cellular processes. (PM=plasma membrane;
OMM=outer mitochondrial matrix; IMM=inner mitochondrial matrix).
doi:10.1371/journal.pone.0009872.g005
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PLoS ONE | www.plosone.org 11 March 2010 | Volume 5 | Issue 3 | e9872Figure 6. Overexpression of mutant CHMP2B produces an aberrant phenotype in HEK-293 cells. Cells were transfected with vectors
encoding recombinant protein c-Myc-CHMP2B with either the wild-type or I29V, T104N or Q206H mutant sequence, and stained with FITC-conjugated
antibody to c-Myc. Transfection with wild-type CHMP2B (A) results in generalised cytoplasmic expression, whereas the mutant isoforms I29V (B), T104N
(C) andQ206H (D) resulted in cytoplasmic vacuolesof varying size (indicated by arrowheads). Another striking observationwas the presence within cells
expression mutant CHMP2B of circular CHMP2B accumulations in the cytoplasm, termed halos (E).Cells were doubly stained with antibodies to c-Myc (F
& I), as well as CD63 (G & J), and merged to show co-localisation (H & K). CD63 co-localises with the small vacuoles found in cells transfected with WT
CHMP2B(F–H). However, CD63 stainingdoesnot co-localise with large vacuoles in mutantexpressing cells(cellstransfectedwith T104N shown), but are
found on the vacuole edge (I–K). Images were taken on a Zeiss LSM 510 confocal microscope, 663 obj. Bar, 10mm.
doi:10.1371/journal.pone.0009872.g006
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such as the Netherlands [51].
In silico analysis of the identified amino acid substitutions
predicts that the p.I29V and p.Q206H mutations decrease
protein stability (http://gpcr2.biocomp.unibo.it/cgi/predictors/
I-Mutant2.0/I-Mutant2.0.cgi). The native threonine of the
p.T104N change is predicted to be a site of phosphorylation
(www.cbs.dtu.dk/services/NetPhos), thus substitution of threonine
with asparagine is predicted to affect protein activity. We did not
identify any of the described codon changes in our 500 controls,
whilst previous studies have sequenced 1495 samples for exon 3
and 2035 samples for exon 6, without identifying the p.T104N and
p.Q206H substitutions [3,4,48,52]. We therefore propose that
these changes are not rare benign polymorphisms, but are
associated with disease. Although the p.I29V substitution has
been reported in a single control sample, as well as in a familial
FTLD case [53], screening of our 500 controls, 640 previously
screened controls, 708 ALS cases and 546 FTD cases [3,4,48,52]
has failed to detect this change. Therefore, whilst it is recognised
that not all missense mutations are pathogenic [54], the clinical,
neuropathological and cellular phenotype common to all 3
CHMP2B mutations, and which is distinct from controls, supports
the proposal that all 3 nucleotide substitutions described in this
report are associated with a lower motor neuron dominant-ALS.
The c.-151C.A polymorphism is predicted to alter the binding
site for an unknown transcription factor (www-bimas.cit.nih.gov/
molbio/index.shtml). However, there is no significant difference in
frequency between subjects and controls (Chi Square p=0.9), and
therefore this change is likely to represent a non-functional
polymorphism.
The pathology is rather stereotypical and, whilst firmly within
the ALS/MND spectrum, appears to represent a rather distinctive
lower motor neuron variant. The inclusion morphology does not
correspond to the predominant pattern seen in classical ALS/
MND, where skein inclusions predominate in ,90% of cases, so
that the absence of classical skeins in this group is distinctive.
Bunina bodies are found in up to 75–80% of ALS/MND cases,
and their absence in these 4 patients is again suggestive of an
atypical group. While these features are not sufficiently distinctive
to allow a morphological prediction of CHMP2B-related MND,
our results indicate that a predominance of compact inclusions in a
PMA case may warrant examination of the CHMP2B gene.
Microarray analysis of the gene expression profile of motor
neurons with CHMP2B mutations compared to neurologically
normal control samples reveals some interesting changes to genes
involved in key cellular processes, many of which are distinct to
those shown by motor neurons isolated from SOD1-related ALS
cases (Kirby et al, manuscript under review). CHMP2B cases show
downregulation in multiple transcripts encoding proteins involved
in the transport of cargoes along microtubules, suggesting
impairments in axonal transport (KIF1A, KIF1C, KIF5C DYNLRB1,
DYNLL2 and DYNC1H1), a phenomenon that has been well
documented in multiple neurodegenerative diseases, including a
SOD1-mediated model of ALS [55]. Interestingly, the dysregula-
tion of microtubule proteins MAP1S, MAP4 [25] and stathmin,
predicts loss of cell structure and transport network. It has been
shown that stathmin overexpression in HeLa cells leads to Golgi
fragmentation and microtubule disassembly, which are the same
events observed in transgenic G93A SOD1 mice [56]. Stathmin
overexpression and Golgi fragmentation seem to be early events in
the neurodegenerative cascade characteristic of ALS and other
neurological diseases [57], and has been confirmed by transcrip-
tional analysis in pre-symptomatic G93A SOD1 mice [19]. ATG1
(3.48 fold) is strongly downregulated, and is part of a complex with
ATG17 and ATG13. This complex is required for the formation of
vesicles at the phagophore assembly site, which is a crucial step for
Figure 7. Mutant CHMP2B causes large cytoplasmic vacuoles.
Cells expressing 3 different mutant CHMP2B had significantly more
vacuoles with an area greater than 1mm
2 in than cells expressing wild-
type protein (One-way ANOVA p,0.0001, +/2: cells grown in DMEM
with FCS, without antibiotic).
doi:10.1371/journal.pone.0009872.g007
Figure 8. LC3-II levels are increased in cells expressing mutant CHMP2B. A representative image of western blotting to LC3 and actin (A),
showing increased levels of LC3-II in COS-7 cells expressing mutant CHMP2B protein (lanes 2–4) compared to cells expressing wild-type protein (lane
1). LC3-II levels relative to an actin loading control were measured using densitometry (B), and this showed increased levels of LC3-II in mutant
expressing cells compared to WT (mean 6S.E.M., n=3) (Mann Whitney p=0.0242). Average fold changes in LC3-II levels normalised to WT are shown
for each of the three mutants (C).
doi:10.1371/journal.pone.0009872.g008
Mutant CHMP2B in LMN-ALS
PLoS ONE | www.plosone.org 13 March 2010 | Volume 5 | Issue 3 | e9872autophagy initiation [30]. A decrease in autophagy initiation may
result in the accumulation of cytosolic aggregates, which could
potentially contribute to motor neuron injury. It is of great interest
that a recent study in a fly model of Huntington’s disease
combined the treatment of rapamycin and lithium [58]. Inhibition
of mTOR by rapamycin and the induction of mTOR-indepen-
dent autophagy by lithium resulted in an increase in autophagy in
both an mTOR-dependent and mTOR-independent manner,
enhanced the clearance of protein aggregates and provided greater
protection than single treatment with either of these molecules
[58]. In addition, our results predict a global repression of protein
translation within the cell due to the downregulation of multiple
translation initiation factors. Translation initiation is a critical
checkpoint and step of the translation process, and is the stage at
which control of mRNA translation is most strongly exerted [59].
This may be an effect of end-stage disease, where the cell is
attempting to survive at the expense of general protein synthesis,
or it may be in response to a compromised ER trying to prevent
accumulation of misfolded proteins. The classical MAPK cascade
and the p38 signalling pathway both show downregulation of
multiple components, alongside upregulation of inhibitors of signal
amplification. This would predict that the cell is unable to respond
normally to stimulation from growth factors, cytokines or
environmental stresses. Downregulation of HSP27, which plays a
role in neuronal survival, in conjunction with the altered
transcriptional levels of MKNK2 and AKT suggests that the motor
neurons are in a state that predisposes to apoptosis. Interestingly,
pharmacological abrogation of p38 by SB203580, resulted in the
accumulation of large autolysosomes [60]. Downregulation of p38
is therefore potentially very important as CHMP2B functions in
degradation and recycling pathways, and mutations result in
autophagosome accumulation [12]. The downregulation of Gaq
and Ga11 suggests a reduction in IP3 levels as a result of decreased
PLCb activity, and this in conjunction with the downregulation of
IP3R, predicts a reduction in calcium release from the ER. In
addition, the upregulation of SERCA and the mitochondrial
calcium transporters NCX1 and VDAC3, may result in excess
calcium being transported out of the mitochondria and into the
ER lumen, having the net effect of an increased [Ca
2+] in the ER
lumen and reduced [Ca
2+] in the mitochondria. Tight control of
ER Ca
2+ stores is crucial for cell survival, and it has been
previously demonstrated that increased ER calcium levels trigger
ceramide-induced apoptosis [61].
We have demonstrated in a HEK-293 cellular model that
transfection of constructs carrying p.I29V, p.T104N or p.Q206H
CHMP2B mutations results in the formation of large cytoplasmic
vacuoles (Figure 6 B–D). Induction of autophagy resulted in an
increase in the number of vacuoles, providing further evidence
that functional CHMP2B is required for the degradation of
cytoplasmic components. These mutations caused aberrant CD63
accumulation within the cytosol (p.T104N: Figure 6 I–J; p.I29V &
p.Q206H: data not shown). CD63 is found abundantly in
lysosomes, and its trafficking and cellular distribution is tightly
regulated [62]. The small vacuoles found in cells expressing WT
CHMP2B co-localised with large areas of CD63 staining –
displaying the normal physiological fusion of late endosomes with
lysosomes (Figure 6 F–H). In contrast, cells expressing mutant
CHMP2B often showed CD63 immunostaining on the mem-
branes of large vacuoles (Figure 6 I–K). These data indicate that
the missense CHMP2B mutations identified in our patient cohort
disrupt the fusion of the lysosome with the large cytoplasmic
vacuoles, suggesting that mutant CHMP2B is altering the
dynamics of this fundamental process. This hypothesis is further
supported by the transfection of FTD-related CHMP2B truncating
mutations in neuroblastoma cell lines, which led to the formation
of large vesicles, with a morphology in keeping with aberrant
endosomes [52].
The MVB pathway has an essential role in the delivery of
ubiquitinated proteins to the lysosome for degradation, and is
highly conserved from yeast to humans. It has been demonstrated
that mice deficient in genes essential for autophagy are unable to
effectively clear cellular debris, leading to the accumulation of
polyubiquitinated proteins within inclusion bodies and subsequent
neurodegeneration [63,64]. Additionally, there is strong evidence
that CHMP2B mutations result in neuronal death; dendritic
retraction and cell death seen in cortical neuron cultures
transfected with CHMP2B
Intron5 is a result of the failure of the
aberrant protein to dissociate from the other subunits of the
ESCRTIII prior to the next round of sorting, a step critical for the
formation of MVBs [12]. Transfection of HeLa cells with
CHMP2B
Intron5 and CHMP2B
D10 results in increased levels of
ubiquitin and p62 and inhibition of protein degradation through
the process of autophagy [13]. Inhibiting autophagy induction in
cells transfected with mutant CHMP2B resulted in delayed
neuronal loss, further implicating autophagy in the process of
neurodegeneration [65,66]. In the present study, we have
demonstrated that LC3-II levels are significantly increased in cells
expressing mutant CHMP2B. Autophagosomes sequester the
target organelle/protein and fuse with lysosomes, where the
contents – and the LC3-II present on the luminal side of the
autophagosome – are degraded [67]. The half-life of LC3-II is
short due to the balance of autophagosome synthesis and
degradation; thus the increased levels of LC3-II in mutant-
expressing cells is indicative of an alteration in the degradation of
cargo by the autophagic pathway. We therefore propose that the
CHMP2B mutations we have identified may contribute to motor
neuron injury through dysfunction of the autophagic clearance of
cellular proteins, and the formation of ubiquitin positive inclusions
with compact morphology (Figure 2). Further mutation screening
now needs to take place in cohorts of patients, particularly those
with a lower motor neuron disease phenotype, and from different
geographical areas. Identification of CHMP2B mutations showing
segregation with familial disease would establish conclusively the
role of CHMP2B as a causative gene in ALS.
Supporting Information
Table S1 The 891 genes downregulated and 561 genes
upregulated in motor neurons with CHMP2B mutations, grouped
into biological processes.
Found at: doi:10.1371/journal.pone.0009872.s001 (0.23 MB
XLS)
Figure S1 Multiple protein alignment of human CHMP2B,
mutant isoforms and orthologues. Amino acids are shaded based
on their properties; polar amino acids are bright, whereas non-
polar residues are darker. Missense mutations identified in the
MND cohort (p.I29V, p.T104N and p.Q206H) are labelled *.
Found at: doi:10.1371/journal.pone.0009872.s002 (5.73 MB
TIF)
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